As the Chief Medical Officer of Apellis Pharmaceuticals, Caroline Baumal leads the company in its vision to innovate in eye care. Her vested stock includes substantial performance-based restricted stock units, valued at $1.8 million as part of her overall compensation...

As the Chief Medical Officer of Apellis Pharmaceuticals, Caroline Baumal leads the company in its vision to innovate in eye care. Her vested stock includes substantial performance-based restricted stock units, valued at $1.8 million as part of her overall compensation in 2023. This stock aligns her financial interests with the company's success and growth. Having joined in early 2023, she quickly established a stake in the company as they prepare for major product launches, particularly focusing on therapies for geographic atrophy and various retinal disorders. These stock units vest based on performance metrics achieved, indicating her commitment to driving the company forward in achieving its goals. Her previous ownership in Potentia Pharmaceuticals and ongoing contributions to research strengthen her position within Apellis, making her a significant figure in the biotech space.